Vanguard Group Inc Cytokinetics Inc Transaction History
Vanguard Group Inc
- $6.44 Trillion
- Q3 2025
A detailed history of Vanguard Group Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 11,856,795 shares of CYTK stock, worth $788 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
11,856,795
Previous 11,983,838
1.06%
Holding current value
$788 Million
Previous $396 Million
64.58%
% of portfolio
0.01%
Previous 0.01%
Shares
18 transactions
Others Institutions Holding CYTK
# of Institutions
445Shares Held
129MCall Options Held
5.25MPut Options Held
1.18M-
T. Rowe Price Investment Management, Inc. Baltimore, MD19.1MShares$1.27 Billion0.64% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$975 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA7.41MShares$492 Million0.07% of portfolio
-
State Street Corp Boston, MA5.62MShares$373 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.3MShares$286 Million7.46% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $6.25B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...